Non-Small Cell Lung Cancer Coverage from Every Angle

Less Frequent Dosing of Nivolumab in NSCLC

By: Joseph Fanelli
Posted: Wednesday, April 3, 2019

Patients with non–small cell lung cancer (NSCLC) experienced similar efficacy and safety results when taking 4- versus 2-week regimens of nivolumab, according to the interim analysis of the CheckMate 384 trial, presented at the 2019 American Society of Clinical Oncology–Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium (Abstract 100) in San Francisco. Edward B. Garon, MD, of David Geffen School of Medicine, University of California, Los Angeles, and colleagues suggest these findings may support a more convenient dosing option in the second-line treatment setting.

Researchers conducted an international, open-label randomized phase IIIb/IV trial in 329 patients with advanced NSCLC who had received prior treatment with nivolumab every 2 weeks for up to 12 months. Patients were randomly assigned to receive a 30-minute infusion of nivolumab at 480 mg every 4 weeks (166 patients) or 240 mg every 2 weeks (163 patients).

Patients on the 4-week regimen had a similar progression-free survival as patients on the 2-week regimen (12.1 months vs. 12.2 months, respectively). The safety profile was also similar, with 48% of the 4-week regimen group reporting any-grade treatment-related adverse events (vs. 61% of the 2-week regimen group). Also, 6% of the 4-week group reported any-grade treatment-related adverse events that led to therapy discontinuation (vs. 9% of the other group). No treatment-related deaths were reported in either group.

In the United States and Canada, nivolumab is approved at 240 mg every 2 weeks or 480 mg every 4 weeks, in the second-line treatment of patients with advanced NSCLC. A final analysis is planned once all study participants have at least 12 months of follow-up.

Disclosure: The study authors’ disclosure information may be found at

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.